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Abstract
Ipilimumab and tremelimumab are humanmonoclonal antibodies (Abs) against cytotoxic T-
lymphocyte antigen-4 (CTLA-4). Ipilimumabwas the first agent to show a statistically significant
benefit in overall survival in advanced melanoma patients. Currently, there is no proven associ-
ation between the BRAFV600mutation and the disease control rate in response to ipilimumab.
This analysis was carried out to assess if BRAFV600 and NRASmutation status affects the
clinical outcome of anti-CTLA-4-treated melanoma patients. This is a retrospective multi-center
analysis of 101 patients, with confirmed BRAF and NRASmutation status, treated with anti-
CTLA-4 antibodies from December 2006 until August 2012. Themedian overall survival,
defined from the treatment start date with the anti-CTLA-4. Abs-treatment to death or till last fol-
low up, of BRAFV600 or NRASmutant patients (n = 62) was 10.12 months (95%CI 6.78–
13.2) compared to 8.26 months (95%CI 6.02–19.9) in BRAFV600/NRASwt subpopulation
(n = 39) (p = 0.67). Themedian OS of NRASmutated patients (n = 24) was 12.1 months and
although was prolonged compared to the median OS of BRAFmutated patients (n = 38,
mOS = 8.03months) or BRAFV600/NRASwt patients (n = 39, mOS = 8.26 months) the differ-
ence didn’t reach statistical significance (p = 0.56). 69 patients were able to complete 4 cycles
of anti-CTLA-4 treatment. Of the 24 patients treated with selected BRAF- or MEK-inhibitors, 16
patients received anti-CTLA 4 Abs following either a BRAF or MEK inhibitor with only 8 of them
being able to finish 4 cycles of treatment. Based on our results, there is no difference in the
median OS in patients treated with anti-CTLA-4 Abs implying that the BRAF/NRASmutation
status alone is not sufficient to predict the outcome of patients treated with anti-CTLA-4 Abs.
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Introduction
Melanoma has been long considered an immunogenic cancer based on reports of spontaneous
regression and some tumor responses after immune-stimulating agent treatment [1–3]. Taking
this into consideration, multiple efforts in cytokine therapy, tumor vaccines, and adoptive
immunotherapy have been pursued to harness the immune response to tackle melanoma but
have had slow progress over the decades [1]. These attempts were limited due to the innate
mechanisms of the immune system preventing its over-activation against self-antigens and as
well to some serious toxic side effects. Inorder to turn on the immune system against cancer
another promishing approach, focused on blocking the negative-regulator of T-cell responses,
the cytotoxic T-lymphocyte-associate antigen (CTLA-4), which marked a new era in the treat-
ment of advanced melanoma and oncoimmunotherapy [4].
Both ipilimumab and tremelimumab are fully human monoclonal antibodies (Abs) against
CTLA-4. Ipilimumab was the first agent to show a statistically significant benefit in overall sur-
vival (OS) in stage IV melanoma patients both in first and second line settings [5,6]. Although
long-durable responses have been reported in a subpopulation of patients, the response rates
are commonly low and currently there are no molecular markers to predict for responders. On
the other hand, tremelimumab failed to significantly improve OS over standard chemotherapy
[7]. This was partly explained due to patients’ selection criteria, as patients with LDH levels
greater than 2x upper limit of normal (2xULN) were excluded according to the study protocol.
Another explanation was the unintended crossover to ipilimumab in the control arm, as cross-
over to tremelimumab was not allowed within the study protocol.
The BRAF oncogene is mutated in approximately 50% of metastatic melanomas [8–11].
Over 90% of the mutations result in substitution of the valine in position 600 (thus V600),
which allows for constitutive activation of the RAS-RAF-MEK-MAPK pathway [12]. This find-
ing made the RAS-RAF-MEK-MAPK pathway the most promising target in melanoma
research and led to the development of targeted therapy against mutated BRAFV600 which
resulted in a treatment-breakthrough with impressive clinical responses and significant pro-
longation of progression-free-survival (PFS) and OS in the majority of advanced melanoma
patients in clinical trials [13–16]. In addition to BRAF, NRAS is mutated in 15–25% of all mela-
nomas, most frequently in exon 1 (G12) and exon 2 (Q61) [17]. These activating NRAS muta-
tions result also in a constitutive activation of the MAP-kinase signal transduction pathway
(MAPK pathway) [18]. It is of interest to note that somatic mutations in the BRAF and NRAS
gene are mutually exclusive [19], thus constitutive activation of the MAPK pathway occurs in
approximately 65–75% of all melanoma tumors.
There is evidence that upon activation of the MAP-kinase pathway an immunosuppressive
phenotype of the tumor is promoted [20]. Whether the mutation status directly correlates with
the clinical outcome remains controversial. Long et al. showed that the presence of an activated
mutation in the BRAF oncogene was associated with a worse clinical outcome but no impact at
the disease free interval [21]. In a small cohort of advanced melanoma patients treated with
bevacizumab and temozolomide, both response and OS were proved to be significantly higher
in the wild-type (wt) population [22]. Nevertheless, and in the retrospective setting, no trend
for a shorter survival in BRAF-mutant patients could be determined [8,23–29]. Recently, the
presence of an NRAS mutation was identified as an independent factor for a worse outcome in
metastatic melanoma [18]. On the other hand Davies et al. suggested NRAS status as a possible
biomarker for response to high dose (HD) interleukin-2 treatment (IL2) [30].
Anti-CTLA-4 Abs are likely to be equally efficacious in both BRAF mutated (BRAFmut)
and wt patients, as they act independently of the MAPK signaling pathway. To date, no associa-
tion between the BRAFV600E mutation and the disease control rate (DCR) after treatment
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with ipilimumab was determined [31]. However, according to preliminary unpublished results
treatment with ipilimumab or the anti-PD1-Ab nivolumab is associated with superior clinical
benefit (increased response rate) in patients harboring the NRAS mutation with no impact in
the PFS or OS [32].
To our knowledge this is the first study to assess if both BRAFV600 and NRAS mutation
status affect the clinical outcome of stage IV melanoma patients treated with anti-CTLA-4 anti-
bodies. We sought to test this hypothesis in a retrospective accrued multicenter cohort of
advanced melanoma patients.
Materials and Methods
Patient Selection and Data Collection
Patients with stage IV metastatic melanoma (American Joint Committee on Cancer, AJCC)
having been treated with anti-CTLA-4 Abs in the period between December 2006 and Octo-
ber 2012 from 5 international melanoma centers with evaluated BRAF and NRAS mutation
status formed the study cohort. Patients with non-resectable stage IIIC AJCC were not
included.
Geographic and histopathologic data including gender, age, melanoma type, localization,
Breslow’s depth, mitotic rate, and presence or absence of ulceration were assessed. Data on
treatment after diagnosis of metastatic disease, including development of new sites of distant
metastases, surgery, systemic therapies, radiotherapy, and survival status were retrospectively
collected for all patients.
Written informed consent for tissue storage including retrospective analysis with collection
of Clinical/laboratory/histology information was previously approved by local ethics commit-
tee (Kantonale Ethikkomission Zürich Biobank/Sammlung von Tumorgewebe, KEK-ZH-Nr.
647). The clinical information was anonymized and de-identified prior to analysis.
Data were classified with dichotomous variables (yes or no) or coded with the quantity of
treatments and metastatic sites. All patients had to be treated at least with one infusion with an
anti-CTLA-4 antibody for a maximum of four infusions (ipilimumab 10mg/kg or 3mg/kg or
tremelimumab 15mg/kg).
OS was defined as the length of time in months from the start of treatment to either death
or last follow up (analysis accounted for censored survival times). Median OS (mOS) in stage
IV disease was defined as the length of time in months from the detection of the first distant
metastasis to death or till last follow up. Treatment duration (TD) was defined as the interval
between the initiation of treatment and treatment discontinuation due to either disease pro-
gression or toxicity and was determined in months (rounded up to a decimal).
Anti-CTLA-4 Antibodies
Eligible patients included BRAFV600- or NRAS-mutated and BRAFV600 and NRAS wild-
type that were treated with the antibody ipilimumab (formerly MDX-010 and MDX-101,
registered as Yervoy; Bristol Myers Squibb, NY, USA) 10mg/kg every three weeks within
the registry trial MDX-020 (clinicaltrials.gov NCT00094653) and 3mg/kg every three
weeks within the available compassionate use program and after the registration in Europe
and Switzerland. Re-induction was allowed in those patients with progression after disease
stabilization. Moreover, four patients were treated with tremelimumab (formerly ticilimu-
mab, CP-675,206; Pfizer, NY, USA) 15 mg/kg every 12 weeks for a maximum of four
infusions.
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Cut-off values LDH and S100B
LDH and S100B were assessed from the patients’ serum. Normal LDH and S100B levels were
defined as lower or equal to the reference cut-off of 480 UI/l and 0.2 ug/l respectively, as
defined by the normal ranges of the biochemical and immunological laboratories of the Uni-
versity Hospital of Zurich.
Mutation Status Assessment
Sections from archival paraffin-embedded samples were tested for BRAF (exon 15) and NRAS
status (exon 2 and 3) at the local departments of dermatology and pathology. The study cohort
included patients treated in clinical trials registered at clinicaltrials.gov (NCT Numbers of the
trials NCT00094653 and NCT00257205). These patients were tested at central labs with more
extensive sequencing. All BRAFwt melanomas were additionally tested for NRAS status. In the
situation where the BRAF and NRAS status was unknown, the mutation status analysis was
performed according to standard procedures at the local laboratories of each center.
Statistical Analysis
Descriptive statistics are presented as percentages of total for categorical variables and as
median for continuous and ordinal variables. For survival time, summary measures include
median overall survival and 95% confidence interval. Chi-squared test and Wilcoxon rank sum
test were used for group comparisons for categorical and continuous parameters. The log rank
test was used for the comparison of survival curves. A Cox proportional hazards model was
used to estimate the adjusted hazard ratio (HR) for treatment duration (TD). Potential con-
founders included the variables mutation status and BRAF / MEK inhibitors. All p-values were
for two-sided test and p<0.05 was considered statistical significance. The analysis was carried
out with Graphpad Prism5 and R-project [33].
Results
A total of one hundred and one (n = 101) AJCC Stage IV melanoma patients treated with anti-
CTLA-4 Abs formed the study cohort. Either loco-regional or distant metastases were used for
BRAF and NRAS mutation testing. One patient had a pW616R-BRAF mutation and a pG10E
mutation in the NRAS oncogene and was classified as BRAFV600/NRASwt. Thirty eight
patients (38%) were mutant for BRAF and twenty four (24%) for NRAS for a total of sixty two
patients with a BRAF or NRAS mutation. Thirty-nine patients (39%) lacked BRAF or NRAS
mutation and were termed as BRAFV600/NRASwt. As of January 2014, eighty three patients
(82%) had passed away and of the eighteen (18%) still alive four were lost to follow up.
Anti-CTLA-4 Antibodies and Treatment Characteristics
Fifteen patients (15%) received anti-CTLA-4 Abs as first line treatment. The median TD in the
complete study cohort (n = 101) was 2.38 months. Sixty-nine patients (69%) were able to com-
plete 4 cycles of anti-CTLA-4 treatment. After completion of anti-CTLA-4 treatment, nine
patients were subsequently treated with BRAF or MEK inhibitors. Sixteen patients received
either a BRAF or MEK inhibitor prior to anti-CTLA-4 treatment with only eight of them
(50%) being able to finish 4 cycles of treatment; two of the patients were re-exposed to BRAF
or MEK inhibition treatment upon progression to anti-CTLA-4 Abs. The rest of the patients
(n = 8) discontinued the treatment either due to progression (n = 7) or due to adverse events
(n = 1) (Fig 1).
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Mutation Status and Patients’ Characteristics
Histopathologic information such as melanoma subtype, localization of primary tumor, and
tumor thickness were known for all patients, while the presence or absence of ulceration was
available in 34% of the patients (n = 34). Patients’ characteristics, demographics and features of
primary and metastatic melanoma in regard to mutation status are listed in Table 1.
BRAFV600 or NRAS mutated patients were younger at time of first diagnosis (median
age = 53, p = 0.004) than the BRAFV600/NRASwt patients (median age 63). No difference in
sex distribution among the two sub-groups was found (p = 0.322). Analyzing the site of the pri-
mary antecedent melanoma, we found that BRAFV600 or NRASmut melanomas were more
frequently located at the trunk and less frequently at the acra, compared to BRAFV600/
NRASwt (p = 0.016) (Table 2).
At stage IV disease forty two patients were staged as M1a or M1b at baseline. The clinical
characteristics of stage IV disease are listed in Table 3. Forty-one patients (41%) developed
brain metastases at some point of stage IV disease. The LDH and S100B levels at stage IV dis-
ease were known in sixty one patients. BRAFV600 or NRASmut patients had higher levels of
S100 and lower levels of LDH, but the difference was not statistically significant (p = 0.26,
p = 0.45, respectively).
Mutation Status and Clinical Outcome
As pointed in the material and methods section, OS was defined from the date of therapy initi-
ation with the anti-CTLA-4 Abs treatment to death or till last follow up. In the complete study
cohort (n = 101), the median OS was 10.08 months. BRAFV600 or NRASmut patients had a
prolonged mOS (mOS = 10.12months, 95% CI 6.78–13.2) compared to BRAFV600/NRASwt
patients (mOS = 8.26 months, 95% CI 6.02–19.9) but did not differ significantly (p = 0.67)
Fig 1. Overview of all anti-CTLA-4 patients according to treatment duration and treatment with BRAF
or MEK inhibitors either prior or after anti-CTLA-4Abs. Each bar represents one patient.
doi:10.1371/journal.pone.0139438.g001
Correlation of Mutation Status and Outcome of Anti-CTLA-4 Ab Patients
PLOS ONE | DOI:10.1371/journal.pone.0139438 October 1, 2015 5 / 12
(Fig 2A). This difference remained non-significant in a multivariate analysis adjusted for age
and gender (Table 4). Also for patients with known LDH and S100 serum levels, there was no
statistically significant difference in the OS when adjusting for high LDH serum levels (n = 80,
HR = 1.52, 95% CI 0.8–2.7, p = 0.152) and high S100 levels (n = 67, HR = 1.570, 95% CI 0.89–
2.77, p = 0.120).
The mOS of NRAS mutated patients (n = 24) was 12.1 months and although it was longer
in absolute numbers compared to the mOS of BRAF mutated patients (n = 38, mOS = 8.03
months) or BRAFV600/NRASwt patients (n = 39, mOS = 8.26months) the difference did not
reach statistical significance (p = 0.56).
MOS in Stage IV disease was 24.7 months (n = 101). The 1-year, 2- and 3-year survival of
the whole study population were 72% (n = 73, 95% CI, 0.62–0.80), 47% (n = 47, 95% CI (0.37–
0.57) and 27% (n = 27, 95% CI 0.18–0.36) respectively. The mOS in Stage IV of BRAFV600 or
NRASmut patients (n = 62) was 20.9 months (95% CI 16.4–32) and was not statistically signifi-
cant compared to BRAFV600/NRASwt patients (n = 39) (mOS = 25.4 months, p = 0.719,
HR = 0.91, 95% CI 13–30.3) (Fig 2B).
Table 1. Patient demographics and primary melanoma characteristics.
Characteristics BRAFV600 or NRAS mut N = 62 BRAF/NRAS wild type N = 39
Age
Median 54.7 60.1
Gender
Male 29 (47%) 23 (59%)
Female 33 (53%) 16 (51%)
Histopathologic subtype
Superﬁcial spreading 11 (17.8%) 3 (7.7%)
Nodular 24 (38.8%) 5 (12.8%)
Acral lentiginous 3 (4.8%) 8 (20.5%)
Lentigo maligna 0 (0%) 1 (2.6%)
Desmoplastic 0 (0%) 1 (2.6%)
Amelanotic 1 (1.6%) 1 (2.6%)
Mucosal 2 (3.2%) 3 (7.7%)
Uveal 0 (0%) 2 (5.1%)
Other* 5 (8%) 0 (0%)
Unknown 16 (25.8%) 15 (38.4%)
Breslow (mm)
0.01–1.0 9 (14.5%) 6 (15.4%)
1.01–2 10 (16.1%) 5 (12.8%)
2.01–4 14 (22.6%) 3 (7.7%)
>4 14 (22.6%) 14 (35.9%)
Unknown 15 (24.2%) 11 (28.2%)
Stage at ﬁrst diagnosis
0 0 (0%) 0 (0%)
I 8 (12.9%) 6 (15.4%)
II 19 (30.6%) 12 (30.8%)
III 21 (33.9%) 13 (33.3%)
IV 6 (9.7%) 3 (7.7%)
Unknown 8 (12.9%) 5 (12.8%)
* including polypoid, solid and melanoma ex naevo.
doi:10.1371/journal.pone.0139438.t001
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Upon the introduction of selective kinase inhibitors in the melanoma market, the standard
of care of melanoma patients has changed. In the BRAFV600 or NRASmut subgroup, twenty
five patients (39%) received a BRAF or MEK inhibitor, and with the exception of vemurafenib,
mostly within clinical trials. Reasons for not obtaining targeted therapy were limited access to
clinical trials, since our study cohort included patients even from 2006. Other reasons include
ineligibility (eg. poor performance status or presence of brain metastases), rapid disease pro-
gression and patient preference. Apart from a favorable prognosis after targeted therapy, an
ECOG performance status less than or equal to 1 is mandated for trial eligibility, which made
an unbiased comparison within the BRAFV600 or NRASmut subgroup not possible. Conse-
quently to avoid bias, patients who received treatment with kinase inhibitors were excluded
from the complete cohort of patients. In this subgroup (n = 76), mOS in Stage IV disease was
20.9 months (95% CI 15.9–32.1) in the BRAFV600 or NRASmut arm and 25.1 months (95%
Table 2. Association of mutation status with age and features of metastatic and antecedent primary melanoma.
Demographic/disease characteristics BRAFV600 or NRAS mut N = 62 (61%) BRAF/NRAS wt N = 39 (39%) p-value
Age
Median 53 (42–62) 63 (55–70) 0.004*
Gender
Male 29 (47%) 23 (59%)
Localization
Acra 3 (5%) 8 (21%) 0.016**
Extremities 16 (26%) 5 (13%)
Trunk 15 (24%) 5 (15%)
LDH elevated 8 (16%), missing 13 8 (26%), missing 8 0.456**
S100 elevated 23 (58%), missing 22 10 (4%), missing 12 0.163**
* Wilcoxon test
** Chi-squared test.
doi:10.1371/journal.pone.0139438.t002
Table 3. Clinical characteristics at stage IV disease according to mutation status.
Characteristics BRAFV600 or NRAS mut N = 62 (61%) BRAF/NRAS wild-type N = 39 (39%)
LDH
Normal 30 19
Elevated 8 8
Unknown 24 12
S100
Normal 17 17
Elevated 23 10
Unknown 22 12
Metastasis category
M1a 10 8
M1b 13 11
M1c 38 17
Unknown 1 3
CNS involvement
Yes 27 14
No 35 25
doi:10.1371/journal.pone.0139438.t003
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CI 12.8–37.7) in the BRAFV600/NRASwt arm (p = 0.96, HR = 0.987) (Fig 2C). When sub-set-
ting for the long survivors (patients with an OS>18months, n = 51) no difference in the mOS
in Stage IV was determined (p = 0.99).
In the BRAFV600 or NRASmut cohort the TD was 2.44 months and did not differ signifi-
cantly compared to the TD of the BRAFV600/NRASwt cohort (TD = 2.55 months, p = 0.84).
In the Cox proportional hazards regression model for OS in the whole study cohort (n = 101),
and after accounting for treatment with BRAF or MEK inhibitors and mutation status, the
determinant TD had a statistically significant association with overall survival in Stage IV dis-
ease (HR = 0.82, p = 0.003), suggesting that longer TD correlates with a lower hazard of death
(Table 5). Same conclusions arise in the cohort without BRAF or MEK inhibitors (n = 76) with
a hazard ratio for TD of 0.81 (p = 0.01) when adjusting for mutation status (Tables 6 and 7).
Discussion and Conclusion
With the recently introduced targeted therapy for BRAF and NRAS mutated melanomas it led
to the question whether the presence or absence of BRAF and NRAS mutation had impact on
survival in melanoma patients treated with anti-CTLA-4 antibodies as well.
Our retrospectively analyzed study-cohort, however, did not confirm this hypothesis. In
fact,the median OS of 10.12 months in BRAFV600 or NRASmut patients was not significantly
longer than the mOSin BRAFV600/NRASwt patients (p = 0.67). These results are in accor-
dance with recently published data by Ascierto et. al [34]. Moreover, previously disease control
rate under anti-CTLA-4 Abs has been reported to be mutation independent [31].
Fig 2. Impact of mutation status on overall survival (OS), defined from initiation of anti-CTLA-4 treatment (Fig 2a) and from stage IV melanoma (Fig
2b) according to BRAF and NRASmutation status in all patients (n = 101). The Fig 2c represents the OS according to mutation status from diagnosis of
metastatic melanoma in the subgroup of patients (n = 76) with no access to BRAF/MEK inhibition treatment.
doi:10.1371/journal.pone.0139438.g002
Table 4. Multivariate Analysis of overall survival (OS) from first medication in all patients (n = 101)
adjusted for age and gender.
All patients, n = 101
Co-variate Hazard Ratio 95% CI p-value
Mutation 0.80 0.50–1.28 0.36
Gender (female = 0) 1.06 0.69–1.63 0.80
Age 1.00 0.98–1.02 0.82
doi:10.1371/journal.pone.0139438.t004
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Nonetheless, there seems to be a trend for longer OS for NRAS mutated patients as com-
pared to BRAF mutated or BRAFV600/NRASwt patients (p = 0.56). This trend is in accordance
with recently published data by Johnson DB et al. elucidating that NRAS mutations can predict
for higher objective and clinical responses from immunotherapy compared to BRAFV600/
NRASwt melanoma [32]. Although in both retrospective analyses the OS did not reach statisti-
cal significance, it seems that NRAS mutated melanoma is more likely to respond to immuno-
therapy. This is an important observation, as NRAS mutant melanoma is associated with
shorter survival [18] and previously showed a correlation with immunotherapeutic agents such
as IL-2 [30] and other treatments [35]. Moreover, the introduction of new very promising mol-
ecules blocking the immune checkpoints including anti-PD-1 antibodies will need prognostic
biomarkers to determine the specific population subset that will benefit from this therapy.
This study also investigated the duration from first distant metastasis to death or till last fol-
low up, termed mOS in stage IV disease. The mOS in stage IV of BRAFV600 or NRASmut
patients was also not statistically significant compared to BRAFV600/NRASwt patients
((p = 0.719, HR = 0.91, 95% CI 13–30.3). As a matter of fact there are different publications
with discrepant results in this context. For example the publication by Carlino et al. is in accor-
dance with our data and concludes that BRAF and NRAS mutation status do not influence sur-
vival in metastatic melanoma [36]. In contrast, Houben et al. found that the presence of either
BRAF or NRAS mutations in melanoma patients was associated with poorer survival [9]. All
these results including ours have high potential for confounding conclusions with respect to
mutation status and overall survival. First of all, there is unquestionably a certain bias in patient
selection. In particular, many patients analyzed here were patients included in clinical trials
that commonly are fitter, healthier and willing to participate to experimental treatments. Sec-
ond, the fact that not all BRAFV600 patients in this cohort received targeted therapy, as this
new treatment option was not standard of care back in 2006, has probably influenced the find-
ings. Yet, in other large unbiased cohorts of stage I/II and stage IV melanoma patients no prog-
nostic impact could be established [28,29]. Finally, population size was limited in this study
and might not have been large enough to see significant trends.
Treatment duration varied across our study population. Only 69% of the patients were able
to complete all 4 cycles of anti-CTLA-4 treatment. This is in accordance to previous observa-
tions in anti-CTLA-4 therapy, where during administration of immunotherapy high dropout
Table 5. Multivariate Analysis of OS in Stage IV in all patients (n = 101) adjusted for treatment duration
(TD) and treatment with BRAF/MEK inhibitors.
All patients, n = 101
Co-variate Hazard Ratio 95% CI p-value
Mutation 0.97 0.59–1.62 0.92
TD 0.82 0.71–0.93 0.003
BRAF/MEKi 0.93 0.46–1.88 0.84
doi:10.1371/journal.pone.0139438.t005
Table 6. Multivariate Analysis of OSin Stage IV in the subgroup of patients without the BRAF/MEK
inhibitors (n = 76).
Without inhibitors, n = 76
Co-variate Hazard Ratio 95% CI p-value
Mutation 1.02 0.61–1.71 0.92
TD 0.80 0.68–0.94 0.009
doi:10.1371/journal.pone.0139438.t006
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rates, are caused either by adverse reactionsor by rapid disease deterioration [37,38]. Interest-
ingly, the determinant TD had a statistically significant association with OS (HR = 0.82,
p = 0.003) and was independent of mutational status. This association suggests that longer TD
correlates with a lower risk of death. However, interpretation of this correlation has to be made
carefully as undoubtedly slow progressive melanoma is more likely to have longer TD and lon-
ger survival as well. Moreover, TD is a factor that cannot be determined a priori and can there-
fore be determined after administration only. Nevertheless, TD could help to identify the
population which is more prone for longer responses and this might affect treatment decisions.
Moreover, as it will be difficult for immunotherapy to use progression-free survival (PFS) as
surrogate marker for OS [39] it will be interesting to evaluate TD in a prospective setting as a
potential surrogate marker for OS in the future.
In concordance to previously reported analysis BRAFV600 or NRAS mutated patients were
younger at time of first diagnosis and no difference in sex distribution among the two sub-
groups was found [40,41]. One patient had a W616R-BRAF mutation and a G10E mutation in
the NRAS oncogene and was classified as BRAFV600/NRASwt. This mutation has to our
knowledge never been described before.
In summary, this study has attempted to define a relationship between mutational status
and immunotherapy in correlation with survival. It is possible that the rapidly changing treat-
ment algorithms over the past few years have influenced the results of this study causing het-
erogeneity of the study population. Moreover, sample size and patient selection might have
influenced these results. Yet, this study is important as it confirms that mutational status is
independent for immunotherapy outcome. In addition, it gives some evidence for better immu-
nologic response in the NRAS mutated population and it supports previously reported charac-
teristics of the BRAFV600 or NRAS population (younger and no difference in gender). Finally,
our data suggest that TD could be used as a potential indicator for prolonged survival.
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